Group 1 - On September 11, 2023, Bluestar Bio-chemical conducted a block trade of 320,000 shares, with a transaction value of 1.6544 million yuan, accounting for 4.68% of the total transaction volume for that day [1][2] - The transaction price was 5.17 yuan per share, which represents a 3% discount compared to the market closing price of 5.33 yuan [1][2]

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-046 江苏蓝丰生物化工股份有限公司 关于控股子公司涉及诉讼的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、案件所处的诉讼阶段：法院已受理，尚未开庭 2、上市公司所处的当事人地位：公司控股子公司安徽旭合新能源科技有限 公司（以下简称"旭合科技"）作为被告 3、涉案金额：11,233,209.17 元 4、对公司损益产生的影响：本次诉讼尚未开庭审理，对本期利润及期后利 润的影响尚不确定。敬请广大投资者关注公司在指定信息披露媒体上披露的相关 公告，理性投资，注意投资风险。 被告：安徽旭合新能源科技有限公司 （二）案件基本情况 江苏昱辉与旭合科技于 2024 年 9 月 5 日签署了《采购合同》，合同签订后 江苏昱辉向旭合科技支付了预付款人民币 300 万元用于后续货款的抵扣。江苏昱 辉以旭合科技部分产品未按时发货为由提起诉讼，要求旭合科技退还未抵扣完的 预付款、提货款及违约金，同时要求旭合科技承担本案的诉讼费。 （三）诉讼请求 1 （1）诉请判令旭合科技向江苏昱辉退还未抵扣完的预 ...

Core Viewpoint - Jiangsu Lanfeng Bio-chemical Co., Ltd. announced that its subsidiary Anhui Xuhe New Energy Technology Co., Ltd. is involved in a lawsuit regarding delayed product shipments, with a claim amounting to 11,233,209.17 yuan [1] Summary by Relevant Sections - **Lawsuit Details** - The plaintiff, Jiangsu Yuhui Sunshine New Energy Co., Ltd., is seeking the return of unutilized prepayments, delivery fees, and penalties due to the late delivery of certain products by Xuhe Technology [1] - The court has accepted the case, but no hearing date has been set yet [1] - **Financial Impact** - The impact of this lawsuit on the company's current and future profits remains uncertain [1] - **Company Response** - Xuhe Technology plans to take measures to protect the rights and interests of the company and its shareholders, and will disclose updates in a timely manner [1]

Core Viewpoint - Jiangsu Lanfeng Biological Chemical Co., Ltd. announced that its major shareholder, Hainan Wenqin Private Fund Management Partnership, plans to reduce its holdings by up to 9,795,589 shares, representing 2.61% of the total share capital [1] Group 1: Shareholder Reduction Details - On September 4, 2025, Hainan Wenqin reduced its holdings by 7,496,000 shares, which is 2.00% of the total share capital, bringing its total holdings down from 33,589,000 shares to 26,093,000 shares, reducing its ownership percentage from 8.95% to 6.95% [2] - The reduction was executed through block trading, and the shares sold were part of a previously disclosed plan [2][3] Group 2: Compliance and Impact - The company confirmed that the reduction does not violate any laws or regulations and does not harm the interests of the company or minority shareholders [3] - The company stated that the reduction will not affect its ongoing operations or control [3]

Group 1 - Baoti shares: The controlling shareholder has increased its stake by 1.004% [1] - Chengda Pharmaceutical: Qianhai Shengtai plans to reduce its holdings by 7.27% [1] - Huawu Co., Ltd.: Nie Jinghua and others plan to reduce their holdings by no more than 3% within three months [1] Group 2 - Changjiang Materials: The controlling shareholder plans to reduce its holdings by no more than 3% [1] - Weishi Electronics: The controlling shareholder's reduction plan does not exceed 3% [1] - Jialian Technology: A related party plans to reduce its holdings by 2.6166% within three months [1] Group 3 - Funeng Technology: Shareholders plan to reduce their holdings by no more than 2% [1] - Lanfeng Biochemical: Hainan Wenqin reduced its holdings by 2.00% [1] - Koweil: Shareholders Jingkun Investment and Hetu Investment plan to reduce their holdings by no more than 2.34% [1] Group 4 - Huayin Power: Hunan Energy plans to reduce its holdings by 1% [1] - Bid Pharmaceutical: Zhoushan Xinxin plans to reduce its holdings by 1.00% [1] - Guanhao High-tech: Shareholder Yuechuang Investment plans to reduce its holdings by no more than 1% [1] Group 5 - Juxin Technology: Zhuhai Chenyour plans to reduce its holdings by no more than 0.5% [1] - Tianji Shares: Shantou Tianji reduced its holdings by 0.61% [1]

Core Points - The company, Bluefeng Biochemical (002513.SZ), announced a significant share reduction by its shareholder Hainan Wenqin [1] Group 1 - Hainan Wenqin reduced its holdings by 7,496,000 shares through a block trade, representing 2.00% of the company's total share capital [1] - Following the reduction, Hainan Wenqin's shareholding decreased from 33,589,000 shares to 26,093,000 shares [1] - The percentage of total share capital held by Hainan Wenqin fell from 8.95% to 6.95% [1]

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-045 江苏蓝丰生物化工股份有限公司 关于持股5%以上股东减持股份触及1%整数倍的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 江苏蓝丰生物化工股份有限公司（简称"公司"）于 2025 年 7 月 30 日在巨潮 资讯网（http://www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股份预 披露公告》（公告编号：2025-035），公司股东海南闻勤私募基金管理合伙企业（有 限合伙）——闻勤顺为 1 号私募证券投资基金（以下简称"海南闻勤"）拟减持公 司股份不超过 9,795,589 股，不超过公司总股本的 2.61%，其中：以集中竞价交易 方式减持的股份数量不超过公司总股本的 1%，以大宗交易方式减持的股份数量不 超过公司总股本的 2%。 近日，公司收到股东海南闻勤出具的《股东减持股份触及 1%整数倍告知函》， 海南闻勤于 2025 年 9 月 4 日通过大宗交易方式减持公司股份 7,496,000 股，占公 司总股本的 2.00%。本次减持后，海南闻勤持有公司的股份由 ...

Group 1 - The core point of the article is that Hainan Wenqin, a shareholder of Lanfeng Biochemical, reduced its stake in the company through a block trade on September 4, 2025, selling 7.496 million shares, which accounts for 2.00% of the total share capital [1] - After the reduction, Hainan Wenqin's shareholding decreased from 33.589 million shares to 26.093 million shares, resulting in a decrease in ownership percentage from 8.95% to 6.95%, which has reached the 1% threshold [1] - As of the announcement date, the reduction plan has not been fully implemented [1]

Group 1 - The core transaction involved 7.496 million shares of Bluestar Bio, with a total transaction value of 38.0047 million yuan, accounting for 39.16% of the total trading volume on that day [1][2] - The transaction price was 5.07 yuan per share, which represents a discount of 1.55% compared to the market closing price of 5.15 yuan [1][2]

Core Viewpoint - Jiangsu Lanfeng Bio-chemical Co., Ltd. has signed a settlement and debt waiver agreement with its controlling shareholder, Jiangsu Suhua Group Co., Ltd., to resolve investor litigation and debt issues, which is expected to alleviate the company's debt pressure and optimize its capital structure [1][7]. Summary by Sections Overview of the Settlement and Debt Waiver - The company faced investor lawsuits due to information disclosure violations, resulting in a compensation requirement of RMB 22,766,475.6, including overdue interest and litigation costs [2]. - As of July 31, 2025, the company owed Jiangsu Suhua Group a total of RMB 83,600,036.66, comprising RMB 59,200,719.70 in principal and RMB 24,399,316.96 in interest [2]. - The company has reached a settlement with Jiangsu Suhua Group regarding the investor lawsuits and debt waiver [2]. Key Terms of the Agreement - Jiangsu Suhua Group will bear a total compensation responsibility of RMB 17,157,200.73 for the investor lawsuits, which will be deducted from the company's outstanding loans to the group [5]. - The agreement includes a waiver of RMB 6,000,000 in interest debt by Jiangsu Suhua Group, which is unconditional and irrevocable [5]. - Following the agreement, the company will not pursue any further claims related to the investor lawsuits against Jiangsu Suhua Group or its management [6]. Impact of the Agreement on the Company - The total amount involved in the settlement and debt waiver is RMB 23,157,200, which will help reduce the company's debt burden and improve its asset-liability structure [7]. - The company will adjust its liabilities according to relevant accounting standards based on the audit results [7].